Iniciar sesión Regístrese gratis

Neovacs S.A Propiedad de la dirección

¿Qué es el Propiedad de la dirección de Neovacs S.A?

El Propiedad de la dirección de Neovacs S.A. es 0.01%

¿Cuál es la definición de Propiedad de la dirección?



La propiedad de personas con información privilegiada se calcula como el número total de acciones propiedad de personas con información privilegiada (accionistas que poseen más del 5% de la corporación o un funcionario o director de la compañía) dividido por el total de Acciones en circulación.

A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.

A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.

Propiedad de la dirección de compañías en Sector Health Care en EURONEXT en comparadas con Neovacs S.A

¿Qué hace Neovacs S.A?

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.

Empresas con propiedad de la dirección similar a Neovacs S.A